[Results of prolonged ethmozine treatment in patients with ventricular arrhythmias].
The results of long-term ethmozine treatment given to 44 patients with ventricular disturbances of the heart rhythm showed that the drug (600-800 mg/day) proved to be 100 percent effective in preventing relapses of ventricular extrasystole and its high gradations including paroxysmal ventricular tachycardia. Furthermore, the patients exhibited good tolerance to ethmozine under conditions of its prolonged continuous administration. The drug at the doses studied exerted no adverse action on the liver, kidney or hemopoietic functions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016293:Moricizine; D010640:Phenothiazines / Q000008:administration & dosage*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine
Rezul'taty dlitel'nogo lecheniia étmozinom bol'nykh s zheludochkovymi narusheniiami ritma serdtsa.